Success Metrics

Clinical Success Rate
85.9%

Based on 158 completed trials

Completion Rate
86%(158/184)
Active Trials
54(16%)
Results Posted
31%(49 trials)
Terminated
26(8%)

Phase Distribution

Ph phase_4
57
17%
Ph phase_2
97
29%
Ph phase_1
43
13%
Ph not_applicable
39
12%
Ph early_phase_1
2
1%
Ph phase_3
91
27%

Phase Distribution

45

Early Stage

97

Mid Stage

148

Late Stage

Phase Distribution329 total trials
Early Phase 1First-in-human
2(0.6%)
Phase 1Safety & dosage
43(13.1%)
Phase 2Efficacy & side effects
97(29.5%)
Phase 3Large-scale testing
91(27.7%)
Phase 4Post-market surveillance
57(17.3%)
N/ANon-phased studies
39(11.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.0%

158 of 195 finished

Non-Completion Rate

19.0%

37 ended early

Currently Active

54

trials recruiting

Total Trials

334

all time

Status Distribution
Active(66)
Completed(158)
Terminated(37)
Other(73)

Detailed Status

Completed158
unknown73
Recruiting36
Terminated26
Active, not recruiting18
Not yet recruiting12

Development Timeline

Analytics

Development Status

Total Trials
334
Active
54
Success Rate
85.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (0.6%)
Phase 143 (13.1%)
Phase 297 (29.5%)
Phase 391 (27.7%)
Phase 457 (17.3%)
N/A39 (11.9%)

Trials by Status

terminated268%
unknown7322%
active_not_recruiting185%
recruiting3611%
completed15847%
withdrawn113%
not_yet_recruiting124%

Recent Activity

Clinical Trials (334)

Showing 20 of 334 trialsScroll for more
NCT06124157Phase 2

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
NCT06317662Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Recruiting
NCT05675410Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Recruiting
NCT06717347Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting
NCT04043494Phase 3

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Recruiting
NCT07571681Phase 2

Colchicine for Autoimmune and Subacute Thyroiditis

Not Yet Recruiting
NCT03959085Phase 3

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Recruiting
NCT06890884Phase 2

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Recruiting
NCT04759586Phase 3

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Active Not Recruiting
NCT03007147Phase 3

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT07565623Not Applicable

Prevention of AIDS With Opportunistic Infection Paradoxical IRIS

Not Yet Recruiting
NCT03914625Phase 3

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

Active Not Recruiting
NCT07005154Phase 2

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Recruiting
NCT03206671Phase 3

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Active Not Recruiting
NCT06624670Phase 3

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Recruiting
NCT07553988Phase 2

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

Active Not Recruiting
NCT05761171Phase 2

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Active Not Recruiting
NCT04078568Phase 3

Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease

Completed
NCT07052929Phase 1

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

Recruiting
NCT01679119Phase 2

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

Completed

Drug Details

Intervention Type
DRUG
Total Trials
334